BPC-157: what the FDA has and hasn’t decided

BPC-157 is not FDA-approved, and as of October 18, 2026 a licensed pharmacy may not compound it for you. Two things happened this year that are easy to misread: in April the FDA took BPC-157 off its Category 2 safety list, and in July an FDA advisory committee voted 8 to 6 to recommend it for one use. Neither step made it legal to compound. This guide sets out what the FDA has decided, what it hasn’t, and what would have to happen before BPC-157 could be prescribed. It doesn’t point to any seller, because there is no lawful source today.

What BPC-157 is

BPC-157 is a lab-made chain of 15 amino acids. It is popular online for injuries, tendon and gut problems, and it is often paired with TB-500 in what sellers call the “Wolverine” stack. Most of the research behind those claims comes from animal and cell studies. On its compounding safety page, the FDA says it has “no, or only limited, safety-related information for the proposed routes of administration” (FDA). There is no FDA-approved BPC-157 product.

What the FDA has decided

Not eligible for compounding

Under section 503A, a pharmacy may compound a medicine only from a bulk ingredient that has a USP or National Formulary monograph, is a component of an FDA-approved drug, or appears on the FDA’s 503A bulks list (FDA interim policy). While the list is being built, the FDA also lets pharmacies use substances in Category 1, those it is still evaluating. BPC-157 meets none of these tests, so it falls outside the FDA’s interim policy.

That has been true for years. In an April 2020 warning letter to a compounding pharmacy, the FDA said compounding with BPC-157 was not eligible for the 503A exemptions (FDA).

Products sold for research are unapproved drugs

In June 2023 the FDA sent a warning letter to an online seller over injectable and nasal-spray BPC-157 and TB-500 labeled for research purposes only. The FDA called them unapproved new drugs (FDA). A label saying a vial is for research doesn’t change what the product is when it is sold for people to inject.

April 2026: off Category 2, into no category

BPC-157 used to sit in Category 2, the FDA’s list of substances that raise significant safety risks. In April 2026, after the groups that nominated it withdrew their nominations, the FDA moved it, with eight other peptides, to a list of substances “nominated but withdrawn”. Its categories list, updated May 14, 2026, places BPC-157 in no category.

This is the step most often misreported. Leaving Category 2 is not the same as entering Category 1. A substance with no nomination has no path to compounding under the interim policy, and the January 2025 version of that policy says a substance nominated after January 7, 2025 isn’t placed in Category 1.

What the FDA hasn’t decided

The July 23, 2026 advisory vote

The FDA’s Pharmacy Compounding Advisory Committee met on July 23, 2026 to consider whether BPC-157 should go on the 503A bulks list for ulcerative colitis, the use its nominator proposed (Federal Register). According to law-firm reports of the meeting, the committee voted 8 to 6 with 1 abstention to recommend it, against the recommendation of the FDA’s own review team (McDermott). The FDA has not posted minutes or an official vote record.

The same day, the committee also voted 8 to 6 for TB-500 (wound healing) and KPV, and 7 to 5 for MOTS-c, according to the same reports.

No rule yet

An advisory committee advises; it doesn’t decide. To add BPC-157 to the bulks list, the FDA would have to:

1. Publish a proposed rule in the Federal Register.
2. Take public comments.
3. Publish a final rule adding BPC-157 to the list in 21 CFR 216.23.

As of October 18, 2026, the FDA has not published a proposed rule for BPC-157 or placed it in Category 1, and its categories list is still the May 14, 2026 version. There is no public timeline for a decision.

What a “yes” would and wouldn’t mean

If the FDA does add BPC-157 to the bulks list, a licensed 503A pharmacy could compound it for an individual patient’s prescription. It would still not be an FDA-approved drug. The FDA would not have reviewed it for safety or effectiveness, and its use for injuries, tendons or general recovery would remain unstudied in large human trials. The committee looked at one use, ulcerative colitis, and its vote doesn’t establish that BPC-157 works for that either.

The evidence gap

The case for BPC-157 rests mostly on animal and lab studies. The FDA’s safety note says it has no, or only limited, safety information for the routes people use, which are injection under the skin and nasal spray, and the FDA’s review team recommended against adding it to the list, according to the reports of the July meeting. Until well-designed human trials are published, no one can say how well it works, at what dose, or what the risks of long-term use are.

Why buying it anyway is a bad idea

BPC-157 is widely sold online as a research chemical, in vials labeled for laboratory research only. Buying these for personal use is unsafe and unregulated. No prescriber decides whether it suits you, no licensed pharmacy answers for what is in the vial, and no one has checked whether it contains what the label says, at the stated strength, free of bacteria and toxins. Injecting a contaminated or mislabeled product can cause infections and other harm, and there is no recourse when it goes wrong.

If a website offers you a “prescription” for compounded BPC-157 today, treat that as a warning sign: it is offering something a licensed pharmacy may not lawfully make. Our guide on whether peptides are safe covers how to check a provider.

What you can do instead

If you are dealing with an injury, gut symptoms or slow recovery, start with a clinician who can diagnose the cause and offer treatments with evidence behind them. If you are interested in peptide therapy, the peptides a pharmacy may lawfully compound today are sermorelin, PT-141 (bremelanotide), oxytocin and topical GHK-Cu, and none of them is a substitute for BPC-157. Our peptide legal status guide lists every popular peptide, and the peptides hub explains how we choose providers.

The bottom line

The FDA hasn’t approved BPC-157 and hasn’t made it eligible for compounding. The April 2026 change removed it from a safety list without putting it on any other, and the July 2026 advisory vote is a recommendation the FDA hasn’t acted on. Until a final rule adds it to the 503A bulks list, there is no lawful prescription source, and products labeled for research only are unsafe and unregulated. We’ll update this page when the FDA publishes a decision.